China’s enrolment rate dips as phase rises

Figure 1: Enrolment rate by trial phase in China. Credit: GlobalData.

On average, enrolment rates for clinical trials in China, which include both single-country and multinational trials, decrease as products move through the pipeline (Figure 1).

GlobalData looked at trials between January 2001 to April 2018 and found that Phase I trials have the highest enrolment rates, enrolling 15.5 subjects/site/month, and have the second largest number of trials, as shown by the bubble size in the figure below.

Phase III trials make up 54.8% of the total trials that were analysed, and have a low enrolment rate of 4.4 subjects/site/month. These later-stage trials often have such slow enrolment rates because they require the largest number of patients per trial.

For more insight and data, visit the GlobalData Report Store – Pharmaceutical Technology is part of GlobalData Plc.